

61
BAKER BOTTS LLPRECEIVED
DEC 15 2003
TECH CENTER 1800/2000**REQUEST
FOR
CONTINUED EXAMINATION (RCE)
TRANSMITTAL**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000,
provides for continued examination of an utility or plant application
filed on or after June 8, 1995.
See The American Inventors Protection Act of 1999 (AIPA).

| | |
|------------------------|----------------------|
| Application Number | 09/910,186 |
| Filing Date | July 20, 2001 |
| First Named Inventor | Leonard Smith et al. |
| Group Art Unit | 1645 |
| Examiner Name | Portner, VA |
| Attorney Docket Number | A33626A 067252.0107 |

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114a. ☐ Previously submittedi. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____

(Any unentered amendment(s) referred to above will be entered).

ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____iii. ☐ Other _____b. ☒ Enclosedi. ☒ Amendment/Replyii. ☐ Affidavit(s)/Declaration(s)iii. ☐ Information Disclosure Statement (IDS)iv. ☐ Other _____**2. Miscellaneous**a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)b. ☐ Other _____**3. Fees** The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 02-4377i. ☒ RCE fee required under 37 C.F.R. § 1.17(e)ii. ☒ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)iii. ☒ Other Any additional charges under 37 CFR 1.16 and 1.117b. ☒ Check in the amount of \$ 1720 enclosedc. ☐ Payment by credit card (Form PTO-2038 enclosed)**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)

Carmella L. Stephens

Registration No. (Attorney/Agent)

41,328

Signature

Carmella L. Stephens

Date

December 3, 2003

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Alexandria, VA 22313-1450, or facsimile transmitted to the US Patent and Trademark Office on:

Name (Print/Type)


Carmella L. Stephens

Signature

Carmella L. Stephens

Date

December 3, 2003



BAKER BOTTS LLP

Attorney Docket Number: A33626A 067252.0107

Title: RECOMBINANT VACCINE AGAINST BOTULINUM NEUROTOXIN

Use Space Below for Additional Information:

This submission includes:

RCE Transmittal (2 sheets);
Petition for Extension of Time (2 sheets);
Fee Transmittal (1 sheet in duplicate);
Amendment (26 sheets);
Two Exhibits (27 sheets);
Terminal Disclaimer (3 sheets);
Sequence Listing in paper form (46 sheets);
Sequence Listing in CRF (1 diskette);
Assignment (6 sheets);
BB Check # 173288; and
Return Postcard.